S
usceptibility testing for the polymyxins has been beleaguered over the years. The polymyxins were first isolated from Paenibacillus polymyxa in 1947 by two independent American groups (1, 2) , and there has been a therapeutic renaissance in the use of both polymyxin B and colistin (polymyxin E) over the last decade, given the rise of multidrug-resistant (MDR) Gram-negative bacilli, such as MDR Acinetobacter and Pseudomonas and carbapenemase-producing Enterobacteriaceae.
Despite susceptibility testing being available for a long time, clarity has been lacking for appropriate methods of testing and optimal dosing for the polymyxins. Polymyxins are cationic polypeptides comprised of a heptapeptide ring, an exocyclic chain, and a fatty acid tail with positively charged residues which interact with and disrupt the Gram-negative lipopolysaccharide membrane; polymyxin B and colistin differ by only one amino acid in the heptapeptide ring (3, 4) . Several reasons have accounted for difficulties with susceptibility testing for the polymyxins, including their cationic nature, their poor diffusion in agar due to their large molecular size, concerns over drug powder composition, and their heteroresistance. Further, the complex pharmacokinetics (PK) and pharmacodynamics (PD) of these compounds and the paucity of data correlating MIC data, drug concentration, and clinical outcomes have made setting clinical breakpoints challenging. The mechanisms underlying polymyxin resistance are complex, and correlation between these has been comprehensively reviewed recently (4) . Complicating this has been the discovery of plasmid-mediated resistance due to mcr-1 and -2 (5, 6) .
Polymyxin susceptibility testing guidance by various professional bodies has varied over the years (e.g., there have been different breakpoints and disk antimicrobial contents for diffusion testing) (7), although efforts have recently been made to harmonize these. In 2016, the joint CLSI-EUCAST polymyxin breakpoint working group agreed that the ISO-20776 standard broth microdilution method (BMD) (which is the same method outlined in CLSI document M07-A010 [8] ) should be used for colistin MIC determination and be performed with sulfate salts of colistin in plain polystyrene trays without additives like polysorbate-80 (P-80) (9) and that diffusion methods should be abandoned. P-80 had at one point been recommended by the CLSI as a supplement for colistin BMD quality control testing (10, 11) to mitigate the cationic properties of the polymyxins, which cause them to adhere to the negatively charged polystyrene surface. However, P-80 in itself has some antibacterial activity and may act synergistically with polymyxins to spuriously lower MICs, especially for organisms for which MICs are in the low range, i.e., near the breakpoints and/or epidemiologic cutoff values of 1 to 2 g/ml (13, 14) . This led to the removal of P-80 from BMD for the polymyxins in CLSI document M100-S27 (15, 16) . Manual BMD, however, is laborious and not performed in many routine clinical microbiology laboratories, which often rely on diffusion or automated systems for susceptibility testing. Moreover, and somewhat paradoxically in view of the drugs' poor diffusion in agar, diffusion methods (both disk and gradient strips) have been found to have unacceptably high levels of false susceptibility (or very major errors [VMEs] ) in multiple studies (12, (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (Table 1) . Both the CLSI and EUCAST have now advised against diffusion methods for the polymyxins, removing disk diffusion interpretive criteria for them from their guidance documents (9, 15, 22) .
Parsing the literature for the comparative performances of the various susceptibility testing methods for the polymyxins may be somewhat confusing, with studies seemingly giving contradictory results; Table 1 attempts to summarize data published from 2001 to date. Several important reasons accounting for these disparities should be borne in mind when evaluating studies. These include different susceptibility breakpoints used and various proportions of isolates studied for which the MICs are near the breakpoint. With regard to the number of isolates near susceptibility breakpoints, studies often lack a sizeable number of resistant isolates (especially resistant isolates for which the polymyxin MICs are low [4 to 8 mg/liter]), which may obscure an accurate estimation of VME rates. These MICs are also of clinical relevance given what we currently know about the pharmacokinetics of polymyxin B and colistin, dose optimization, and target attainment (29, 30) . Indeed, VMEs or major errors (MEs) may be underreported if the MICs for the isolates studied fall into extremes, with either very high MICs (high-level resistance) or very low MICs (very susceptible isolates). VME rates should also be calculated with the number of resistant isolates as the denominator and ME rates with susceptible isolates as the denominator, rather than expressed as a percentage of the total number of isolates (12) . Unfortunately, the literature has not been consistent, and VMEs and MEs have often been expressed as percentages of the number of isolates tested (resistant and susceptible) ( Table 1 , footnote c). Studies may also vary depending on the relative proportions of Enterobacteriaceae and/or nonfermenting Gram-negative bacilli, and heteroresistance has been described in some species, such as Enterobacter, Pseudomonas aeruginosa, and Acinetobacter spp. The most important reason for the variation of reported results in the literature for polymyxin antimicrobial susceptibility testing (AST), however, has been the lack of consensus in what constitutes a "gold standard" comparator. Until further data are available, per CLSI-EUCAST guidance, BMD with no supplementation should be the standard comparator.
In this issue, Chew et al. (31) pragmatically evaluate four commercial polymyxin B and colistin AST methods commonly used and/or more easily implemented in routine clinical microbiology laboratories than BMD performed by the reference ISO-20776 As determined by the gold standard comparator used in the study.
c VMEs were presented with the denominator as the total number of isolates tested but were recalculated from figures presented in the paper in this table and presented as a percentage, with the denominator as the number of total resistant isolates tested.
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standard (8, 9) . These comprise a commercial BMD system (Sensititre), gradient diffusion (Etest), and two automated AST systems: Vitek 2 and MicroScan (colistin only). A total of 76 Enterobacteriaceae were studied, including 21 isolates harboring mcr-1. Using the EUCAST colistin resistance breakpoint of Ͼ2 mg/liter for Enterobacteriaceae and applying the same to polymyxin B, the authors found high levels of essential and categorical agreement (EA and CA, respectively) for polymyxin B with Sensititre and Vitek 2 (both Ͼ90%); for colistin, EA was 89.5% for Sensititre and 93.4% for Vitek 2. Due to limited dilutions, EA was not assessed for MicroScan. CA for colistin was 88.2% for MicroScan and Vitek 2 and 90.1% for Sensititre. VME rates for all commercial systems assessed, however, were in excess of the 1.5% recommended by the FDA (12), although in this comparison, Sensititre and MicroScan achieved the lowest VME rate for colistin (VME rate, 4%), and Sensititre and Vitek 2 achieved the lowest VME rate for polymyxin B (VME rate, 3.7%) (only 1 VME for both compounds with these systems). Using FDA requirements, the Etest did not meet acceptance criteria for EA, CA, VMEs, and MEs for polymyxin B and met CA criteria (92.1%) for colistin only. As the authors point out, the VME rates of Ͼ1.5% may be in part due to the relatively small (although comparable to those of previous studies) number of resistant isolates in their study. Larger studies with more resistant isolates may allow a more comprehensive assessment. Overall, the study by Chew et al. (31) found Sensititre to be generally reliable for polymyxin B and colistin, although it tended to overcall resistance, and it found Vitek 2 to have an unacceptable false-susceptibility (VME) rate with colistin, although interestingly, it performed similarly to Sensititre with polymyxin B. MicroScan with colistin (despite having limited dilutions) performed similarly to Sensititre. The findings with the Sensititre panel are in keeping with previously published data (27) and a recent evaluation by EUCAST, which also examined other commercial BMD methods (e.g., Micronaut-S and Micronaut MIC Strip, SensiTest [Liofilchem] , and UMIC [Biocentric]) (32, 33) . It should be noted that not all commercial BMD systems perform alike and that few data are available for some systems, like the BD Phoenix; unpublished data from one evaluation with this system found an unacceptable VME rate of 15% (4) .
The strengths of Chew et al.'s study include the utilization of the ISO-20776 reference BMD as the gold standard and the multiple commercial AST methods studied, which will be of interest to clinical laboratories seeking to evaluate a method for AST of the polymyxins. This is also the largest multimethod comparison, to date, on mcr-1-positive Enterobacteriaceae. Interestingly, the authors note that, if a colistin susceptibility breakpoint of Յ2 mg/liter is used, the Sensititre and MicroScan systems would detect 100% of the mcr-1-positive isolates included in their study (compared to only 71.4% by the reference method, BMD) and that the Sensititre and Vitek systems would detect 95.2% (compared to 81% by BMD) using the same breakpoint with polymyxin B. By reference BMD, six and four mcr-1-positive isolates, respectively, had colistin and polymyxin B MICs of Յ2 mg/liter. In an analysis with lower simulated breakpoints for polymyxin B and colistin (susceptible Currently, the CLSI and EUCAST share harmonized colistin breakpoints for Pseudomonas aeruginosa and Acinetobacter spp. (susceptible, Յ2 mg/liter). For the Enterobacteriaceae, EUCAST adopts the same colistin breakpoints, but the CLSI has yet to set these, although it adopts 2 mg/liter as the epidemiologic cutoff value (ECOFF) for Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Enterobacter cloacae, and Raoultella ornithinolytica. Clinical breakpoints are meaningful if they delineate an MIC for which there is a high probability of clinical response to properly dosed antibiotics. However, robust data correlating MICs, drug concentrations, and clinical outcomes of the polymyxins are very limited, and a clear correlation has not always been demonstrated (34) . Retrospective correlative studies are also difficult to perform because polymyxin resistance may be lost upon subculture and storage (4). Less than 40% of patients with normal or augmented renal function, however, are able to achieve a steady-state plasma colistin concentration of 2 mg/liter, which has been proposed as a surrogate target for the optimization of the area under the curve of free or unbound drug at the MIC for the bacterial pathogen (fAUC/MIC), the PK/PD parameter that predicts treatment success (29) . PK data lend support to lowering the current colistin breakpoints. The simulated lowered breakpoint analyses (with the introduction of an "intermediate" category) by Chew et al. was also found to improve CA and diminished VME and ME rates. Lowering breakpoints would bring about some technical challenges, however, as these would fall within the wild-type MIC distribution of isolates (Յ2 mg/liter), and there remain concerns over the reliability of current testing systems to parse out S and R adequately. Perhaps, as the authors suggest, adding an intermediate category would help reflect these uncertainties in testing and also address the concerns over current dosing strategies and target attainment. More importantly, actual clinical correlative data are sorely needed.
With polymyxin B, there are even fewer comparative data for AST and PK, although the CLSI has breakpoints for Acinetobacter and P. aeruginosa. This lack of data is somewhat historic, as traditionally, colistin has been more widely used in North America and Europe, with correspondingly more studies performed, despite the fact it is administered as a prodrug, colistimethate, of which only about up to a quarter is converted to active colistin in vivo (4) . In contrast, polymyxin B is administered in its active form, and target concentrations are more easily achieved, with less interpatient variability, and its PK is independent of renal function (30) , making it a more attractive option for clinical use than colistin. Although polymyxin B MICs generally trend within Ϯ1 dilution with colistin (10, 31, 35) , they are different drugs, and AST should ideally be performed individually. Besides considering the format of the assay adopted, individual laboratories should carefully weigh, with clinician input, the preferred polymyxin at their institutions when introducing susceptibility testing for this class of antibiotics.
The study by Chew et al. included 21 mcr-1-positive isolates, for a number of which strains MICs were Յ2 mg/liter. Laboratories performing surveillance should note that surveillance criteria by current breakpoints may not always identify all isolates with mcr-1. The implications of polymyxin therapy for infections caused by the isolates for which MICs are low are uncertain, as there are currently no clinical outcome data. While the promoter sequences upstream of mcr-1 in the current study were examined and found to be intact, the actual level of mcr-1 expression was not determined in their study, and it is plausible that phenotypic resistance may become apparent only after polymyxin exposure. A recent study found that for transformants with mcr-1, the colistin MICs were usually 16-fold or higher (except for Pseudomonas aeruginosa, for which MICs were only modestly increased) (36) . The possibility that mcr-1 isolates for which polymyxin MICs are low may remain undetected and silently spread is somewhat disconcerting given that mcr-1 and -2 are plasmid borne and may be shared by horizontal gene transfer. A lower breakpoint was found to increase the rate of detection of mcr-1-positive isolates in the authors' study across all methods, although the utility of such an approach would need to be examined with further in vitro and clinical data, which will hopefully also help shed light on the extent and clinical significance of this phenomenon.
The study performed by Chew et al. (31) indicates that commercial and automated BMD systems, which are in reach of most routine microbiology laboratories, may provide results fairly comparable to those of the reference, BMD. Future assessments will be strengthened by including larger numbers of isolates, especially those with polymyxin resistance and MICs straddling existing or putative breakpoints. It is also anticipated that impending regulatory changes will soon lead to FDA-cleared tests for the polymyxins (16) . Future studies should focus on correlating microbiologic, PK, and clinical outcome data. For this to happen, quality assurance standards utilized in determining the potencies of clinically administered drugs also need to be reassessed and updated, given that these still rely on derivatives of diffusion-based methods (37) . Nevertheless, the adoption of a standard reference methodology and continued harmonization of breakpoints by the CLSI and EUCAST, along with work such as that by
